AI Article Synopsis

  • Current long-term risk prediction models for breast cancer are not fully utilizing past mammogram images, and dynamic models have not been explored for routine medical use.
  • A study examined a large group of women, analyzing their mammogram data over time to create a dynamic model that predicts the 5-year risk of developing breast cancer.
  • The results showed that incorporating previous mammogram images significantly improved risk prediction, identifying high-risk women who could benefit from further screening or preventive measures.

Article Abstract

Purpose: Current image-based long-term risk prediction models do not fully use previous screening mammogram images. Dynamic prediction models have not been investigated for use in routine care.

Methods: We analyzed a prospective WashU clinic-based cohort of 10,099 cancer-free women at entry (between November 3, 2008 and February 2012). Follow-up through 2020 identified 478 pathology-confirmed breast cancers (BCs). The cohort included 27% Black women. An external validation cohort (Emory) included 18,360 women screened from 2013, followed through 2020. This included 42% Black women and 332 pathology-confirmed BC excluding those diagnosed within 6 months of screening. We trained a dynamic model using repeated screening mammograms at WashU to predict 5-year risk. This opportunistic screening service presented a range of mammogram images for each woman. We applied the model to the external validation data to evaluate discrimination performance (AUC) and calibrated to US SEER.

Results: Using 3 years of previous mammogram images available at the current screening visit, we obtained a 5-year AUC of 0.80 (95% CI, 0.78 to 0.83) in the external validation. This represents a significant improvement over the current visit mammogram AUC 0.74 (95% CI, 0.71 to 0.77; < .01) in the same women. When calibrated, a risk ratio of 21.1 was observed comparing high (>4%) to very low (<0.3%) 5-year risk. The dynamic model classified 16% of the cohort as high risk among whom 61% of all BCs were diagnosed. The dynamic model performed comparably in Black and White women.

Conclusion: Adding previous screening mammogram images improves 5-year BC risk prediction beyond static models. It can identify women at high risk who might benefit from supplemental screening or risk-reduction strategies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11634085PMC
http://dx.doi.org/10.1200/CCI-24-00200DOI Listing

Publication Analysis

Top Keywords

mammogram images
12
external validation
12
model repeated
8
prediction models
8
black women
8
screening
5
women
5
development validation
4
validation dynamic
4
dynamic 5-year
4

Similar Publications

Classifying the molecular subtype of breast cancer using vision transformer and convolutional neural network features.

Breast Cancer Res Treat

January 2025

Department of Radiological Technology, Faculty of Medical Technology, Niigata University of Health and Welfare, 1398 Shimamichou, Kita-Ku, Niigata, Japan.

Purpose: Identification of the molecular subtypes in breast cancer allows to optimize treatment strategies, but usually requires invasive needle biopsy. Recently, non-invasive imaging has emerged as promising means to classify them. Magnetic resonance imaging is often used for this purpose because it is three-dimensional and highly informative.

View Article and Find Full Text PDF

Comparing synthetic mammograms based on wide-angle digital breast tomosynthesis with digital mammograms.

J Med Imaging (Bellingham)

January 2025

Lund University, Department of Translational Medicine, Medical Radiation Physics, Malmö, Sweden.

Purpose: We aim to investigate the characteristics and evaluate the performance of synthetic mammograms (SMs) based on wide-angle digital breast tomosynthesis (DBT) compared with digital mammography (DM).

Approach: Fifty cases with both synthetic and digital mammograms were selected from the Malmö Breast Tomosynthesis Screening Trial. They were categorized into five groups consisting of normal cases and recalled cases with false-positive and true-positive findings from DM and DBT only.

View Article and Find Full Text PDF

Breast Suspicious Microcalcifications on Contrast-Enhanced Mammograms: Practice and Reflection.

Int J Gen Med

January 2025

Department of Radiology, Huangpu Branch, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200011, People's Republic of China.

Purpose: To evaluate the use of contrast enhanced mammography (CEM) in suspicious microcalcifications and to discuss strategies to cope with its diagnostic limitations.

Methods: We retrospectively evaluated patients with suspicious calcifications who underwent CEM at our institution. We collected and analyzed morphological findings, enhancement patterns and pathological findings of suspicious microcalcifications on CEM.

View Article and Find Full Text PDF

Breast cancer is the most prevalent cancer in women in Europe, and while all European countries have some form of screening for breast cancer, disparities in organization and implementation exist. Breast density is a well-established risk factor for breast cancer; however, most countries in Europe do not have recommendations in place for notification of breast density or additional supplementary imaging for women with dense breasts. Various supplemental screening modalities have been investigated in Europe, and when comparing modalities, MRI has been shown to be superior in cancer detection rate and in detecting small invasive disease that may impact long-term survival, as demonstrated in the Dense Tissue and Early Breast Neoplasm Screening (DENSE) trial in the Netherlands.

View Article and Find Full Text PDF

Rationale And Objectives: To develop a machine learning (ML) model based on clinicopathological and imaging features to predict the Human Epidermal Growth Factor Receptor 2 (HER2) positive expression (HER2-p) of breast cancer (BC), and to compare its performance with that of a logistic regression (LR) model.

Materials And Methods: A total of 2541 consecutive female patients with pathologically confirmed primary breast lesions were enrolled in this study. Based on chronological order, 2034 patients treated between January 2018 and December 2022 were designated as the retrospective development cohort, while 507 patients treated between January 2023 and May 2024 were designated as the prospective validation cohort.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!